WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 406623
Description: SMK-17 is a potent MEK1/2 inhibitor with high aqueous solubility. SMK-17 inhibited MEK1 kinase activity in a non-ATP-competitive manner and it was highly selective to MEK1 and 2. SMK-17 inhibited the growth of tumor cell lines in vitro. Moreover, unlike previously reported MEK inhibitors, PD184352 or U0126, SMK-17 did not inhibit the phosphorylation of ERK5. In vivo, SMK-17 exhibited potent antitumor activity in animal models on oral administration. SMK-17 selectively blocked the MAPK pathway signaling without affecting other signal pathways, which resulted in significant antitumor efficacy without notable side effects.
MedKoo Cat#: 406623
Chemical Formula: C20H24ClF2IN4O2S
Exact Mass: 584.03212
Molecular Weight: 584.85
Elemental Analysis: C, 41.07; H, 4.14; Cl, 6.06; F, 6.50; I, 21.70; N, 9.58; O, 5.47; S, 5.48
SMK-17 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to email@example.com to inquire quote.
Synonym: SMK17; SMK 17; SMK17.
IUPAC/Chemical Name: N-(2-((2-chloro-4-iodophenyl)amino)-3,4-difluorophenyl)-4-(isopropylamino)piperidine-1-sulfonamide
InChi Key: WEULUYVOTSCFRJ-UHFFFAOYSA-N
InChi Code: InChI=1S/C20H24ClF2IN4O2S/c1-12(2)25-14-7-9-28(10-8-14)31(29,30)27-18-6-4-16(22)19(23)20(18)26-17-5-3-13(24)11-15(17)21/h3-6,11-12,14,25-27H,7-10H2,1-2H3
SMILES Code: O=S(N1CCC(NC(C)C)CC1)(NC2=CC=C(F)C(F)=C2NC3=CC=C(I)C=C3Cl)=O
The following data is based on the product molecular weight 584.85 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1. Kiga, M. Method for predicting responsiveness to MAPK signaling pathway-inhibiting compound by detecting mutation of ÃŽÂ²-catenin, reagent for detecting the mutation, and treatment of cancer with MAPK signaling pathway inhibitor. WO2014133071A1.